FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Russian patent published in 2021 - IPC C07K14/50 C07K19/00 A61K38/18 C12P21/02 A61P1/16 A61P3/04 A61P3/06 A61P3/10 

FIELD: biotechnology.

SUBSTANCE: invention relates to fibroblast growth factor (FGF21) 21 fibroblast proteins, and can be used in medicine for treating FGF21-associated disorders selected from a group, consisting of diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Fused protein contains a mutant FGF21 and an immunoglobulin Fc region, wherein the FGF21 mutant protein is bound to the immunoglobulin Fc region by a peptide linker of 10–30 amino acid residues, where the linker is connected to the C-terminus of the immunoglobulin Fc region and the N-terminus of the mutant protein FGF21. Also disclosed are a nucleic acid, an expression vector and a host cell for producing the FGF21-Fc fusion protein by a recombinant method.

EFFECT: invention enables to obtain FGF21-based fusion protein with improved in vivo durability, stability and pharmacological efficacy.

12 cl, 6 tbl, 7 ex, 12 dwg